PuSH - Publication Server of Helmholtz Zentrum München

Falkenberg, N. ; Anastasov, N. ; Rappl, K. ; Braselmann, H. ; Auer, G.* ; Walch, A.K. ; Huber, M. ; Höfig, I. ; Schmitt, M.* ; Höfler, H. ; Atkinson, M.J. ; Aubele, M.

MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion.

Br. J. Cancer 109, 2714-2723 (2013)
Publ. Version/Full Text Volltext DOI PMC
Free by publisher
Open Access Green as soon as Postprint is submitted to ZB.
Background:MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells.Methods:MiR-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT-PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222.Results:In tumour tissues, miR-221/-222 were associated with the occurrence of distant metastases. In particular, high levels of miR-221 were revealed to have a high prognostic impact for the identification of significantly different groups with advanced tumours. MiR-221/-222 overexpression strongly increased cell proliferation and invasion in vitro. Following miR-221/-222 overexpression an increased uPAR expression and cell invasion were observed.Conclusion:This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Therapy ; Prognosticator ; Prognosis ; Metastasis ; Malignancy ; Mir-221 ; Mir-222 ; Urokinase-type Plasminogen Activator System ; Upar; Urokinase Plasminogen-activator ; Estrogen-receptor-alpha ; Messenger-rna ; Tamoxifen Resistance ; Down-regulation ; Expression ; Micrornas ; Metastasis ; Survival ; Mir-222
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Journal British Journal of Cancer BJC
Quellenangaben Volume: 109, Issue: 10, Pages: 2714-2723 Article Number: , Supplement: ,
Publisher Nature Publishing Group
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Pathology (PATH)
Institute of Radiation Biology (ISB)
Translational Metabolic Oncology (TMO)
Research Unit Analytical Pathology (AAP)